Related Experiment Video
Updated: Feb 3, 2026

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
Structure-based assessment and network analysis of targeting 14-3-3 proteins in prostate cancer
Alex Root1, Azadeh Beizaei2, H Alexander Ebhardt3
1Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
Developing combination therapy for castrate-resistant prostate cancer (CRPC) may require exploiting new drug targets outside androgen receptor and PI3K / AKT / mTOR signal transduction pathways implicated in prostate cancer (PCa) progression. One such possible new target is YWHAZ of the 14-3-3 protein family as this gene has prognostic significance for metastatic CRPC patients. However, there are no small molecules targeting YWHAZ commercially available. Hence, we explored whether the small molecule BV02 targeting another 14-3-3 protein family member SFN also binds to YWHAZ. Using advanced docking algorithms we find that BV02 docks many other 14-3-3 family members. In addition, the amphipathic groove where drug binding occurs also has a high binding affinity for other drugs used to treat PCa such as docetaxel. The proteome of metastatic PCa models (LNCaP clone FGC and PC-3) was perturbed as a result of BV02 treatment. Through data integration of three proteomics data sets we found that BV02 modulates numerous protein-protein interactions involving 14-3-3 proteins in our PCa models.
Insights
Researchers explored novel drug targets for castrate-resistant prostate cancer (CRPC), investigating YWHAZ and the small molecule BV02. BV02 shows potential for targeting 14-3-3 proteins in prostate cancer models.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Castrate-resistant prostate cancer (CRPC) treatment requires novel targets beyond androgen receptor and PI3K/AKT/mTOR pathways.
- YWHAZ, a 14-3-3 protein family member, is a potential prognostic target for metastatic CRPC, but lacks specific small molecule inhibitors.
- The study investigates BV02, a small molecule targeting SFN (another 14-3-3 protein), for its potential to bind YWHAZ.
Discussion:
- Advanced docking algorithms predict BV02 binds to multiple 14-3-3 family members, including YWHAZ.
- The drug-binding site on 14-3-3 proteins also shows affinity for docetaxel, a known prostate cancer therapeutic.
- BV02 treatment perturbs the proteome in metastatic prostate cancer models (LNCaP clone FGC and PC-3).
Key Insights:
- BV02 demonstrates binding to YWHAZ and other 14-3-3 proteins, suggesting a broader targeting capability.
- Proteomic analysis reveals BV02 modulates protein-protein interactions involving 14-3-3 proteins in prostate cancer.
- Data integration of proteomics datasets confirms BV02's impact on 14-3-3 mediated interactions.
Outlook:
- BV02 represents a potential therapeutic lead for targeting 14-3-3 proteins in CRPC.
- Further research is warranted to validate YWHAZ as a therapeutic target and BV02's efficacy in vivo.
- This study opens avenues for developing novel combination therapies for advanced prostate cancer.
Related Concept Videos
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Protein Networks
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
Piaget's Stage 3 of Cognitive Development
Conservation and Constancy of Quantity
A significant cognitive milestone in the...
Structural Protein Function
Collagen, the most abundant protein in mammals, is found throughout the body. In connective tissue, such as skin, ligaments, and tendons, it provides tensile strength and elasticity. In bones and teeth, it mineralizes to...

